Capricor Therapeutics Inc (CAPR) - Total Liabilities
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has total liabilities worth $47.58 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Capricor Therapeutics Inc (CAPR) long-term investment share to see how much of total assets are deployed in long-term investments.
Capricor Therapeutics Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CAPR total assets.
Capricor Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Capricor Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
eDreams Odigeo SA
MC:EDR
|
Spain | €929.05 Million |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
Sweden | Skr1.16 Billion |
|
Basler Kantonalbank
SW:BSKP
|
Switzerland | CHF51.12 Billion |
|
Ningbo Bohui Chemical Technology
SHE:300839
|
China | CN¥1.31 Billion |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
China | CN¥1.48 Billion |
|
Hangzhou Chinastars Reflective Material Co.Ltd.
SHE:301077
|
China | CN¥682.93 Million |
|
Chularat Hospital Public Company Limited
BK:CHG
|
Thailand | ฿1.97 Billion |
|
Yantai Longyuan Power Tech
SHE:300105
|
China | CN¥806.00 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Capricor Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CAPR equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Capricor Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual total liabilities of Capricor Therapeutics Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.16 Million | +100.48% |
| 2024-12-31 | $25.02 Million | -30.76% |
| 2023-12-31 | $36.13 Million | -5.68% |
| 2022-12-31 | $38.31 Million | +284.54% |
| 2021-12-31 | $9.96 Million | +55.20% |
| 2020-12-31 | $6.42 Million | +50.18% |
| 2019-12-31 | $4.27 Million | -7.71% |
| 2018-12-31 | $4.63 Million | -8.23% |
| 2017-12-31 | $5.05 Million | -77.82% |
| 2016-12-31 | $22.75 Million | +33.03% |
| 2015-12-31 | $17.10 Million | -13.98% |
| 2014-12-31 | $19.88 Million | +227.38% |
| 2013-12-31 | $6.07 Million | +1047.61% |
| 2012-12-31 | $529.17K | -2.27% |
| 2011-12-31 | $541.45K | -49.35% |
| 2010-12-31 | $1.07 Million | +67.69% |
| 2009-12-31 | $637.55K | -52.13% |
| 2008-12-31 | $1.33 Million | -29.51% |
| 2007-12-31 | $1.89 Million | +1301.86% |
| 2006-12-31 | $134.78K | +73.00% |
| 2005-12-31 | $77.91K | +31.16% |
| 2004-12-31 | $59.40K | +42.22% |
| 2003-12-31 | $41.77K | +70.09% |
| 2002-12-31 | $24.55K | +167.33% |
| 2001-12-31 | $9.19K | +920.56% |
| 2000-12-31 | $900.00 | 0.00% |
| 1999-12-31 | $900.00 | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more